Overview
- Recent peer-reviewed analysis cited by the NHS reports that over a recent five-year span there were no recorded cervical cancer deaths among women in their early 20s in England, a change researchers link to the national HPV immunisation programme.
- The NHS and research teams from Queen Mary University of London and Cancer Research UK estimate the vaccine rollout has prevented roughly 200 cervical cancer deaths in England since it began in 2008.
- Officials stress the vaccine protects against the high-risk HPV types that cause most cervical cancers but does not cover all cancer-causing strains, so routine cervical screening remains essential for detection.
- Uptake fell in some areas after the COVID-19 pandemic and coverage remains uneven across regions, prompting calls for action to raise and equalise vaccination rates and to offer free catch-up doses to eligible young people.
- Public-health experts note this result reflects early vaccinated cohorts and expect population benefits to evolve as those groups age, while warning that large gaps in global vaccine access mean most cervical cancer deaths still occur in poorer countries.